Simon A, Cuisset L, Vincent M F, van Der Velde-Visser S D, Delpech M, van Der Meer J W, Drenth J P
University Medical Center St. Radboud, Box 9101, 6500 HB Nijmegen, the Netherlands.
Ann Intern Med. 2001 Sep 4;135(5):338-43. doi: 10.7326/0003-4819-135-5-200109040-00010.
The hyper-IgD and periodic fever syndrome (HIDS) is characterized by recurrent attacks of fever, abdominal distress, and arthralgia and is caused by mevalonate kinase mutations.
To ascertain the role of mevalonate kinase and the usefulness of molecular diagnosis in HIDS.
Cross-sectional study.
The international Nijmegen HIDS registry.
54 patients from 41 families who met the clinical criteria for HIDS.
Clinical symptoms and signs, immunoglobulin concentration, leukocyte count, erythrocyte sedimentation rate, mutation analysis, and mevalonate kinase enzyme activity assay.
There were two groups of patients: 41 patients with mevalonate kinase mutations (classic-type HIDS) and 13 patients without mutations (variant-type HIDS). Patients with classic-type HIDS had a lower mevalonate kinase enzyme activity, a higher IgD level, and more additional symptoms with attacks. The IgD level did not correlate with disease severity, mevalonate kinase enzyme activity, or genotype.
Genetic heterogeneity exists among patients with a clinical diagnosis of HIDS.
高IgD血症和周期性发热综合征(HIDS)的特征为发热、腹部不适和关节痛反复发作,由甲羟戊酸激酶突变引起。
确定甲羟戊酸激酶的作用以及分子诊断在HIDS中的实用性。
横断面研究。
国际奈梅亨HIDS注册中心。
来自41个家庭的54例符合HIDS临床标准的患者。
临床症状和体征、免疫球蛋白浓度、白细胞计数、红细胞沉降率、突变分析以及甲羟戊酸激酶酶活性测定。
患者分为两组:41例有甲羟戊酸激酶突变的患者(经典型HIDS)和13例无突变的患者(变异型HIDS)。经典型HIDS患者的甲羟戊酸激酶酶活性较低,IgD水平较高,发作时伴有更多其他症状。IgD水平与疾病严重程度、甲羟戊酸激酶酶活性或基因型均无相关性。
临床诊断为HIDS的患者存在遗传异质性。